Epigenetic Changes in Alzheimer’s Disease and Interventions for Therapy

Mingjing Xu,1,* Lijun Xiong,2,* Zhenjuan Qin,3,* Xinyi Yu,4,* Tao Chen,4,* Xinxin Zhang,1,* Mingyue Jin,5,* Liping Wang,2,* Longqiang Cai,3,* Yuhua Wei,3,* Huihua Liu,3,* Chengqiang Wang,2 Huilin Hu,3,* Zhenyou Zou1,3– 5 1School of Public Health, Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 2College of Biotechnology, Guilin Medical University, Guilin, Guangxi, People’s Republic of China; 3Key Laboratory of Mental Disorders and Prevention, Guangxi Zhuang Autonomous Region Brain Hospital, Liuzhou, Guangxi, People’s Republic of China; 4School of Public Health, Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, People’s Republic of China; 5Department of Genetic Disease Research, Osaka Metropolitan University, Osaka, Japan*These authors contributed equally to this workCorrespondence: Zhenyou Zou, Email [email protected] Chengqiang Wang, Email [email protected]: With the ageing of society, the number of Alzheimer’s disease (AD) patients has increased rapidly, imposing a heavy burden on families and society. This article reviews the causes of AD, particularly the epigenetic changes associated with AD, including DNA methylation, histone modifications, and noncoding RNA changes. The development of diagnostic reagents based on biomarkers specific to epigenetic changes and attempts to intervene in adverse epigenetic factor changes in AD for the treatment of AD are discussed. This review contributes to a better understanding of the relationship between epigenetics and AD and provides guidance for exploring diagnostic and therapeutic strategies.Keywords: Alzheimer’s disease, epigenetics, DNA methylation, histone modification, noncoding RNA